What's Happening?
Tango Therapeutics, in collaboration with Revolution Medicines, has reported a significant breakthrough in the treatment of pancreatic cancer. Their experimental PRMT5 inhibitor, when combined with Revolution Medicines' RAS inhibitor, achieved a 92% response
rate in patients with advanced MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC). This response rate surpasses previous results seen with either drug used alone or in combination with chemotherapy. The data comes from an ongoing Phase 1/2 study, which also showed a 100% disease control rate and a 90% six-month progression-free survival rate among the 12 patients involved. The trial's success has led Tango to plan for registrational trials in the front-line setting, with the potential for accelerated development in first-line MTAP-deleted pancreatic cancer.
Why It's Important?
This development is significant as pancreatic cancer is notoriously difficult to treat, with limited options available and a low survival rate. The 92% response rate achieved in this trial represents a major advancement in the field, offering hope for improved outcomes for patients with this aggressive cancer. The success of the combination therapy could lead to new treatment protocols and potentially expedite regulatory approval processes. The positive trial results have also impacted the financial markets, with Tango's stock price rising significantly. This breakthrough underscores the potential of targeted therapies in oncology, particularly for cancers with specific genetic mutations.
What's Next?
Following the promising results, Tango Therapeutics is preparing to advance into Phase 3 trials for first-line treatment of MTAP-deleted pancreatic cancer. The company is also considering expanding the use of the combination therapy to second-line treatments, pending feedback from regulatory bodies. The Food and Drug Administration (FDA) is expected to play a crucial role in the next steps, as the unprecedented activity seen in the trial may influence their decision-making process. The biotech community and investors will be closely monitoring these developments, as successful regulatory approval could set a new standard in pancreatic cancer treatment.
